3SBio Sells Shares, Divests Subsidiary To Boost Capital

Benzinga_recent_news12-11

After grabbing the spotlight this year with a big licensing deal, the Chinese drug developer is now raising extra funds for R&D and shedding a non-core subsidiary Buoyed by a stock rally, Chinese drug...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590590792?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/11/image.png?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2025-12-11 19:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590590792","market":"sh","top_or_hot":-1,"title":"3SBio Sells Shares, Divests Subsidiary To Boost Capital","media":"Benzinga_recent_news","content":"<div>\n<p>After grabbing the spotlight this year with a big licensing deal, the Chinese drug developer is now raising extra funds for R&D and shedding a non-core subsidiary\nBuoyed by a stock rally, Chinese drug...</p>\n\n<a href=\"https://www.benzinga.com/Opinion/25/12/49328004/3sbio-sells-shares-divests-subsidiary-to-boost-capital\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3SBio Sells Shares, Divests Subsidiary To Boost Capital</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3SBio Sells Shares, Divests Subsidiary To Boost Capital\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-11 19:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/Opinion/25/12/49328004/3sbio-sells-shares-divests-subsidiary-to-boost-capital><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After grabbing the spotlight this year with a big licensing deal, the Chinese drug developer is now raising extra funds for R&D and shedding a non-core subsidiary\nBuoyed by a stock rally, Chinese drug...</p>\n\n<a href=\"https://www.benzinga.com/Opinion/25/12/49328004/3sbio-sells-shares-divests-subsidiary-to-boost-capital\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2097828557.USD","symbol_name":"AZ EQUITY CHINA \"A\" (USD) ACC","start_time":0,"source_url":"https://www.benzinga.com/Opinion/25/12/49328004/3sbio-sells-shares-divests-subsidiary-to-boost-capital","article_id":"2590590792","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/11/image.png?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/Opinion/25/12/49328004/3sbio-sells-shares-divests-subsidiary-to-boost-capital","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2590590792","pubTimestamp":1765452180,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"After grabbing the spotlight this year with a big licensing deal, the Chinese drug developer is now raising extra funds for R&D and shedding a non-core subsidiary. After its market value rose above HK$70 billion, the companyannouncedon Dec. 2 it was placing 105 million shares, or about 4.14% of its enlarged share capital, to raise additional money to invest in the highly competitive field of innovative drugs. The shares were priced at HK$29.62, a 6.5% discount to the previous closing price, with net proceeds after fees estimated at HK$3.09 billion.This plan aligns with 3SBio's strategic shift in recent years toward prioritizing innovation. From 2022 to 2024, the company's R&D expenditure rose from 690 million yuan to 1.33 billion yuan, while the research bill in the first half of 2025 was 15% higher than in the same period a year earlier. The company has 30 experimental drugs in its pipeline, including 27 innovative treatments spanning oncology and autoimmune diseases. Among them, four","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK0196":"行业龙头","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","BK0239":"医药制造","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","BK0183":"MSCI概念","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK0188":"融资融券","BK0012":"证金概念","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","BK0028":"国家队","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1997245177.USD":"安联神洲A股基金","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","BK0060":"抗癌","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC"},"translate_title":"三生制药出售股份、剥离子公司以增资","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1},"content_text":"After grabbing the spotlight this year with a big licensing deal, the Chinese drug developer is now raising extra funds for R&D and shedding a non-core subsidiary\nBuoyed by a stock rally, Chinese drug developer 3SBio Inc. (1530.HK) is bulking up on funds to meet the challenge of delivering next-generation cancer medicines.\nFresh from a blockbuster rights deal with drugs giant Pfizer earlier this year, 3SBio has announced a subsidiary spin-off and a HK$3.12 billion ($400 million) share placement in the space of just two weeks.\nAfter its market value rose above HK$70 billion, the company announced on Dec. 2 it was placing 105 million shares, or about 4.14% of its enlarged share capital, to raise additional money to invest in the highly competitive field of innovative drugs. The shares were priced at HK$29.62, a 6.5% discount to the previous closing price, with net proceeds after fees estimated at HK$3.09 billion.\nThe company's shares fell 4.61% on day of the placement news and another 3.04% in the next session but are up more than 400% in the year to date, underscoring market confidence in the brand's long-term prospects.\nJust a couple of weeks earlier, 3SBio had revealed plans to hive off a money-spinning subsidiary that specializes in hair-loss treatments, Mandi International, as it doubles down on developing novel bio-pharmaceutical drugs for cancer and auto-immune conditions.\nAt first glance, 3SBio does not appear to be short of cash. In May, the company granted Pfizer (PFE.US) international rights to a bispecific antibody drug targeting the PD-1/VEGF pathways for an upfront payment of up to $1.25 billion (8.8 billion yuan), setting a Chinese record for such deals. That downpayment is expected to be booked in the third quarter. Meanwhile, 3SBio turned a first-half net profit of 1.36 billion yuan, indicating a solid financial foundation.\nWhy did 3SBio choose to raise more capital right now? Based on the company's statement, the aim is to build an R&D cash buffer to develop its candidate drugs and expand its share of the innovative medicine market.\nOf the placement proceeds, 80% will go towards R&D costs such as funding ongoing clinical trials in China and the United States, expanding the use of existing drugs to treat further conditions, and boosting global infrastructure and facilities. The remaining 20% will be used as working capital.\nThis plan aligns with 3SBio's strategic shift in recent years toward prioritizing innovation. From 2022 to 2024, the company's R&D expenditure rose from 690 million yuan to 1.33 billion yuan, while the research bill in the first half of 2025 was 15% higher than in the same period a year earlier. The company has 30 experimental drugs in its pipeline, including 27 innovative treatments spanning oncology and autoimmune diseases. Among them, four candidates are undergoing parallel clinical trials in China and the United States and are being readied for regulatory filings, with hefty sums needed to synchronize the cross-border development.\nMeanwhile, 3SBio is divesting from its Mandi subsidiary, the leader in China's hair-loss treatment sector for a decade with a 71% share of the market for the alopecia medication minoxidil. Mandi logged first-half revenues of 743 million yuan, with a gross margin of 81.1% and net profit reaching 174 million yuan.\nDespite the financial benefits, Mandi's consumer healthcare profile does not fit the strategic focus on novel pharmaceuticals. Hence 3SBio is divesting its entire 87.16% stake and spinning off Mandi as an independent listed entity,in a process known as distribution in kind, in which shareholders will be directly assigned a pro-rata stake, leaving the parent with no equity interest.\nThis clean break differs from the approach adopted by other companies such as WuXi Biologics (2269.HK), which retained a controlling stake when it hived off WuXi XDC (2268.HK), a unit specializing in antibody-drug conjugates.\nDeveloping viable new drugs is a capital-intensive enterprise, and parent companies typically retain cash-generating businesses to subsidize their R&D. Cutting ties with Mandi underscores 3SBio's resolve to transform into a pure-play pharmaceutical company, bolstered by cash reserves and a late-stage drug pipeline.\nDespite appearing flush with cash, the company must prepare in advance for potentially substantial funding needs going forward, after divesting its cash-generating operations.\nAt present, 3SBio trades at a price-to-earnings ratio of approximately 28 times, lagging the roughly 60 times for another established innovator, Hengrui Pharma (1276.HK; 600276.SH), and suggesting future upside potential.\nAs the company secures capital and executes the spin-off, investors will be keen to see whether 3SBio can press ahead with its drug ambitions and deliver meaningful breakthroughs.\nBenzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga’s reporting and has not been edited for content or accuracy.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590590792","isCrawlerRequest":true}